Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Translating molecular advances in fragile X syndrome into therapy: a review.

Hagerman RJ, Des-Portes V, Gasparini F, Jacquemont S, Gomez-Mancilla B.

J Clin Psychiatry. 2014 Apr;75(4):e294-307. doi: 10.4088/JCP.13r08714. Review.

PMID:
24813413
2.

New insights into the molecular pathophysiology of fragile X syndrome and therapeutic perspectives from the animal model.

Busquets-Garcia A, Maldonado R, Ozaita A.

Int J Biochem Cell Biol. 2014 Aug;53:121-6. doi: 10.1016/j.biocel.2014.05.004. Epub 2014 May 14. Review.

PMID:
24831882
3.

Advances in understanding fragile X syndrome and related disorders.

Rooms L, Kooy RF.

Curr Opin Pediatr. 2011 Dec;23(6):601-6. doi: 10.1097/MOP.0b013e32834c7f1a. Review.

PMID:
22001764
4.

Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention.

Bhogal B, Jongens TA.

Dis Model Mech. 2010 Nov-Dec;3(11-12):693-700. doi: 10.1242/dmm.002006. Epub 2010 Aug 3. Review.

5.

Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model.

Gantois I, Vandesompele J, Speleman F, Reyniers E, D'Hooge R, Severijnen LA, Willemsen R, Tassone F, Kooy RF.

Neurobiol Dis. 2006 Feb;21(2):346-57. Epub 2005 Sep 30.

PMID:
16199166
6.

Fragile X syndrome and targeted treatment trials.

Hagerman R, Lauterborn J, Au J, Berry-Kravis E.

Results Probl Cell Differ. 2012;54:297-335. doi: 10.1007/978-3-642-21649-7_17. Review.

7.

Fragile X syndrome: from molecular genetics to therapy.

D'Hulst C, Kooy RF.

J Med Genet. 2009 Sep;46(9):577-84. doi: 10.1136/jmg.2008.064667. Review.

PMID:
19724010
8.

Fragile X syndrome: from gene discovery to therapy.

Heulens I, Kooy F.

Front Biosci (Landmark Ed). 2011 Jan 1;16:1211-32. Review.

PMID:
21196228
9.

Mechanism-based approaches to treating fragile X.

Dölen G, Carpenter RL, Ocain TD, Bear MF.

Pharmacol Ther. 2010 Jul;127(1):78-93. doi: 10.1016/j.pharmthera.2010.02.008. Epub 2010 Mar 18. Review.

PMID:
20303363
10.

Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model.

Heulens I, D'Hulst C, Van Dam D, De Deyn PP, Kooy RF.

Behav Brain Res. 2012 Apr 1;229(1):244-9. doi: 10.1016/j.bbr.2012.01.031. Epub 2012 Jan 21.

PMID:
22285772
11.

Protective effects of melatonin against oxidative stress in Fmr1 knockout mice: a therapeutic research model for the fragile X syndrome.

Romero-Zerbo Y, Decara J, el Bekay R, Sanchez-Salido L, Del Arco-Herrera I, de Fonseca FR, de Diego-Otero Y.

J Pineal Res. 2009 Mar;46(2):224-34. doi: 10.1111/j.1600-079X.2008.00653.x. Epub 2008 Dec 23.

PMID:
19141086
12.

Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome.

Koukoui SD, Chaudhuri A.

Brain Res Rev. 2007 Jan;53(1):27-38. Epub 2006 Jul 17. Review.

PMID:
16844227
13.

Biomedical research. A fix for fragile X syndrome?

Miller G.

Science. 2006 Apr 28;312(5773):521. No abstract available.

PMID:
16645065
14.

The pathophysiology of fragile x syndrome.

Penagarikano O, Mulle JG, Warren ST.

Annu Rev Genomics Hum Genet. 2007;8:109-29. Review.

PMID:
17477822
15.

Decreased expression of the GABAA receptor in fragile X syndrome.

D'Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, Kooy RF.

Brain Res. 2006 Nov 22;1121(1):238-45. Epub 2006 Oct 16.

PMID:
17046729
16.

Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome.

el Bekay R, Romero-Zerbo Y, Decara J, Sanchez-Salido L, Del Arco-Herrera I, Rodríguez-de Fonseca F, de Diego-Otero Y.

Eur J Neurosci. 2007 Dec;26(11):3169-80. Epub 2007 Nov 14.

PMID:
18005058
17.

[Fragile X, fulminant hepatitis: new hope].

Nau JY.

Rev Med Suisse. 2011 Feb 16;7(282):418-9. French. No abstract available.

PMID:
21416872
18.

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome.

Scharf SH, Jaeschke G, Wettstein JG, Lindemann L.

Curr Opin Pharmacol. 2015 Feb;20:124-34. doi: 10.1016/j.coph.2014.11.004. Epub 2014 Dec 2. Review.

PMID:
25488569
19.

Fragile X disappointments upset autism ambitions.

Mullard A.

Nat Rev Drug Discov. 2015 Mar;14(3):151-3. doi: 10.1038/nrd4555. No abstract available.

PMID:
25722228
20.

Fragile X syndrome: molecular mechanisms of cognitive dysfunction.

Huber K.

Am J Psychiatry. 2007 Apr;164(4):556. No abstract available.

PMID:
17403966

Supplemental Content

Support Center